Oppenheimer lowered the firm’s price target on Allogene Therapeutics to $13 from $14 and keeps an Outperform rating on the shares. Allogene obtained development and commercialization oncology rights to the EU and UK for its CD19-directed allogeneic cell therapies from Servier and expects the Phase 2 ALPHA3 1st-line Consolidation Large B-cell Lymphoma trial to start in mid-2024 and Phase 1 Relapsed/Refractory Chronic Lymphocytic Leukemia data by YE24, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Biotech Alert: Searches spiking for these stocks today
- Allogene Therapeutics price target lowered to $9 from $10 at H.C. Wainwright
- Allogene Therapeutics price target raised to $4.60 from $4.40 at Stifel
- Allogene Therapeutics 37.93M share priced at $2.90
- Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
